Frank C. Barone, PhD
Joined SUNY Downstate Medical Center in 2008
Professor of Neurology
Director of Basic Research, Cerebrovascular Division
Professor of Physiology & Pharmacology
Medical Student Research Adviser
phone: (718) 221-5745
- Basic scientific study of Cerebrovascular diseases with focus on stroke, vascular cognitive impairment, risk factors, brain injury and restoration of function, and progression to dementia
- Development of animal models of human disease that can translate well to man and can facilitate our understanding of disease biology, pathology and cellular signaling
- Investigation of pharmacologic and other intervention approaches that reduce brain injury and restore lost brain functioning
- Pursue Biomarker Discovery required to impact drug discovery and advance therapeutic interventions
- Maintain close collaborations with Clinical Researchers and Neuroscientists in efforts to support Translational Medicine
- Pathophysiology of brain injury and mechanisms of brain recovery, especially cognition, in cerebrovascular disease - stroke
- Interactions of cerebrovascular risk and other diseases in aging and the progression of dementia
- Pharmacology, Neuropharmacology, Biochemistry, Drug Discovery and Animal Models of Disease.
Education and training:
- PhD: Biopsychology-Neuroscience, Brain Research Laboratory, Syracuse University
- Research Assistant Professor : Syracuse University, 4 years
- Director Discovery Research : GlaxoSmithKline, 25 years
- Adjunct Faculty / Professor: Temple University Medical School, Department of Physiology – 20 years; Thomas Jefferson University, Department of Pharmacology and Biochemistry – 10 years
- Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp Neurol. 2008 Jul;212(1):53-62.
- Lenhard SC, Strittmatter R, Price WJ, Chandra S, White RF, Barone FC. Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine. Pharmacology. 2008;81(1):1-10.
- Barone FC, Endogenous brain protection: models, gene expression, and mechanisms. Methods Mol Med. 2005;104:105-84.
- Maguire S, Strittmatter R, Chandra S, Barone FC. Stroke-prone rats exhibit prolonged behavioral deficits without increased brain injury: an indication of disrupted post-stroke brain recovery of function. Neurosci Lett. 2004 Jan 16;354(3):229-33.
- Legos JJ, Barone FC. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs. 2003 Jul;4(7):847-58.
- McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E. Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):715-20.
- Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC. Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. Stroke. 2002 Feb;33(2):578-85.
- Read SJ, Parsons AA, Harrison DC, Philpott K, Kabnick K, O' Brien S, Clark S, Brawner M, Bates S, Gloger I, Legos JJ, Barone FC. Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. J Cereb Blood Flow Metab. 2001 Jul;21(7):755-78.
- Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med Res Rev. 2001 Mar;21(2):129-45.
- Barone FC, Ohlstein EH, Hunter AJ, Campbell CA, Hadingham SH, Parsons AA, Yang Y, Shohami E. Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S357-61.
- Currie RW, Ellison JA, White RF, Feuerstein GZ, Wang X, Barone FC. Benign focal ischemic preconditioning induces neuronal Hsp70 and prolonged astrogliosis with expression of Hsp27. Brain Res. 2000 Apr 28;863(1-2):169-81.
- Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab. 1999 Aug;19(8):819-34.
- Velier JJ, Ellison JA, Kikly KK, Spera PA, Barone FC, Feuerstein GZ. Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat. J Neurosci. 1999 Jul 15;19(14):5932-41.
- Barone FC, White RF, Spera PA, Ellison J, Currie RW, Wang X, Feuerstein GZ. Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke. 1998 Sep;29(9):1937-50; discussion 1950-1.
- Feuerstein GZ, Wang X, Barone FC. The role of cytokines in the neuropathology of stroke and neurotrauma. Neuroimmunomodulation. 1998 May-Aug;5(3-4):143-59.
- Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998 May;29(5):1020-30.
- Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, Feuerstein GZ. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke. 1997 Jun;28(6):1233-44.
- Barone FC, Feuerstein GZ, White RF. Brain cooling during transient focal ischemia provides complete neuroprotection. Neurosci Biobehav Rev. 1997 Jan;21(1):31-44.